



Drug Discovery

Anti-aging Drugs

From Basic Research to Clinical Practice

Edited by Alexander M. Vaiserman



Anti-aging Drugs

From Basic Research to Clinical Practice

RSC Drug Discovery Series

Editor-in-chief

Professor David Thurston, *King's College, London, UK*

Series Editors:

Professor David Rotella, *Montclair State University, USA*

Professor Ana Martinez, *Centro de Investigaciones Biologicas-CSIC, Madrid, Spain*

Dr David Fox, *Vulpine Science and Learning, UK*

Advisor to the Board:

Professor Robin Ganellin, *University College London, UK*

Titles in the Series:

- 1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups
- 2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1
- 3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2
- 4: Accounts in Drug Discovery
- 5: New Frontiers in Chemical Biology
- 6: Animal Models for Neurodegenerative Disease
- 7: Neurodegeneration
- 8: G Protein-Coupled Receptors
- 9: Pharmaceutical Process Development
- 10: Extracellular and Intracellular Signaling
- 11: New Synthetic Technologies in Medicinal Chemistry
- 12: New Horizons in Predictive Toxicology
- 13: Drug Design Strategies: Quantitative Approaches
- 14: Neglected Diseases and Drug Discovery
- 15: Biomedical Imaging
- 16: Pharmaceutical Salts and Cocrystals
- 17: Polyamine Drug Discovery
- 18: Proteinases as Drug Targets
- 19: Kinase Drug Discovery
- 20: Drug Design Strategies: Computational Techniques and Applications
- 21: Designing Multi-Target Drugs
- 22: Nanostructured Biomaterials for Overcoming Biological Barriers
- 23: Physico-Chemical and Computational Approaches to Drug Discovery
- 24: Biomarkers for Traumatic Brain Injury
- 25: Drug Discovery from Natural Products
- 26: Anti-Inflammatory Drug Discovery
- 27: New Therapeutic Strategies for Type 2 Diabetes: Small Molecules
- 28: Drug Discovery for Psychiatric Disorders
- 29: Organic Chemistry of Drug Degradation
- 30: Computational Approaches to Nuclear Receptors

- 31: Traditional Chinese Medicine
- 32: Successful Strategies for the Discovery of Antiviral Drugs
- 33: Comprehensive Biomarker Discovery and Validation for Clinical Application
- 34: Emerging Drugs and Targets for Parkinson's Disease
- 35: Pain Therapeutics; Current and Future Treatment Paradigms
- 36: Biotherapeutics: Recent Developments using Chemical and Molecular Biology
- 37: Inhibitors of Molecular Chaperones as Therapeutic Agents
- 38: Orphan Drugs and Rare Diseases
- 39: Ion Channel Drug Discovery
- 40: Macrocycles in Drug Discovery
- 41: Human-based Systems for Translational Research
- 42: Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics
- 43: Carbohydrates in Drug Design and Discovery
- 44: Drug Discovery for Schizophrenia
- 45: Cardiovascular and Metabolic Disease: Scientific Discoveries and New Therapies
- 46: Green Chemistry Strategies for Drug Discovery
- 47: Fragment-Based Drug Discovery
- 48: Epigenetics for Drug Discovery
- 49: New Horizons in Predictive Drug Metabolism and Pharmacokinetics
- 50: Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation
- 51: Nanomedicines: Design, Delivery and Detection
- 52: Synthetic Methods in Drug Discovery: Volume 1
- 53: Synthetic Methods in Drug Discovery: Volume 2
- 54: Drug Transporters: Role and Importance in ADME and Drug Development
- 55: Drug Transporters: Recent Advances and Emerging Technologies
- 56: Allosterism in Drug Discovery
- 57: Anti-aging Drugs: From Basic Research to Clinical Practice

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House,
Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,

Email: booksales@rsc.org

Visit our website at www.rsc.org/books

Anti-aging Drugs

From Basic Research to Clinical Practice

Edited by

Alexander M. Vaiserman

Institute of Gerontology, Kiev, Ukraine

Email: vaiserman@geront.kiev.ua



RSC Drug Discovery Series No. 57

Print ISBN: 978-1-78262-435-6

PDF eISBN: 978-1-78262-660-2

EPUB eISBN: 978-1-78262-985-6

ISSN: 2041-3203

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2017

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

Whilst this material has been produced with all due care, The Royal Society of Chemistry cannot be held responsible or liable for its accuracy and completeness, nor for any consequences arising from any errors or the use of the information contained in this publication. The publication of advertisements does not constitute any endorsement by The Royal Society of Chemistry or Authors of any products advertised. The views and opinions advanced by contributors do not necessarily reflect those of The Royal Society of Chemistry which shall not be liable for any resulting loss or damage arising as a result of reliance upon this material.

The Royal Society of Chemistry is a charity, registered in England and Wales, Number 207890, and a company incorporated in England by Royal Charter (Registered No. RC000524), registered office: Burlington House, Piccadilly, London W1J 0BA, UK, Telephone: +44 (0) 207 4378 6556.

Visit our website at www.rsc.org/books

Printed in the United Kingdom by CPI Group (UK) Ltd, Croydon, CR0 4YY, UK

Foreword

In 1970, the world's largest learned society focused on aging underwent a schism that persists to this day. Denham Harman, one of the foremost American gerontologists of that era, had become so incensed at the flight from translational work—or even, to judge from public pronouncements, translational aspirations—of nearly all his colleagues that he felt it necessary to found the American Aging Association in direct competition with the Gerontological Society of America, which had overseen the field for the previous quarter-century.

Was that a good move? This excellent volume provides a fitting affirmative answer. The American Aging Association languished in genuine obscurity and neglect for over 20 years, but by 2000 it had risen to a much greater degree of respect, and it has since become arguably the most prestigious society in the field worldwide, without ever losing sight of its intervention-focused roots. It has done so because of real progress in the laboratory: progress that has shifted other communities to a more translation-friendly stance rather than the other way around.

The pharmacological approach that dominates the following chapters is by no means the only option available to the biomedical gerontologist; in particular, my own work and that of SENS Research Foundation is focused mainly on stem cell and gene therapies. But it remains apparent that pharmacological interventions, simply by virtue of being so much easier to administer, are of immense value even if they only provide much lesser benefit to the average older person than more exotic alternatives, not only because even modest benefit is better than nothing, but also because the latter will not be available for a while and the former can act as a bridge to them.

The first and last sections of this book are no less important. Biogerontology runs the same risk as any science, of becoming an echo-chamber immune to the need for interaction with wider society. Biologists of aging

are perhaps even more duty-bound than any scientists, in consequence of the humanitarian importance of their field, to avoid falling into such a trap. It is therefore laudable that Vaiserman has chosen to invite chapters covering the pros and cons of both the feasibility and the desirability of significant, near-term success in the age-old quest to extend our youth. As one who has dedicated his life to that mission, I can attest that the best way to further it is to discuss it.

Enjoy these chapters as much as I have. They jointly constitute a comprehensive and invaluable primer in the current state of pharmacological anti-aging medicine.

Aubrey de Grey

Preface

Over the last few years, anti-aging medicine has received increasing attention in both public and scientific communities. Public interest in this area of research is largely driven by media attention related to recent developments in regenerative medicine and genome modification technologies. Probably the most famous example of that is the case of Elizabeth Parrish, the CEO of Seattle-based biotech firm BioViva, who claims that she had managed to reverse her own aging process with CRISPR gene editing technology by receiving a treatment targeting two gene loci, one a gene controlling telomere length and the other to protect against loss of muscle mass with age. Even though no confirmation has been received so far on whether or not this technology successfully changed her genome, many safety, ethical and regulatory issues are raised from this case. First of all, this concern is related to possible side effects associated with the use of this technology, primarily cancer. In this respect, using the more conventional pharmacologically based approach seems a reasonable alternative, particularly since many natural and synthetic agents have shown great potential for promoting health and longevity in numerous animal models. Among them, the most attention is currently drawn to rapamycin, resveratrol and the antidiabetic drug metformin. The last one was recently approved by the FDA to be examined in the Targeting Aging with Metformin (TAME) clinical trial to establish whether it may reduce the risk for aging-associated pathologies, such as cognitive impairments, cardiovascular disease and cancer, in non-diabetic persons. If successful, the TAME study would be the first demonstration that a particular drug can prevent or delay the onset of aging-associated chronic human disorders. It might provide a novel regulatory pathway for further clinical trials of pharmaceuticals specifically designed to slow the aging process.

The present volume is the first one devoted entirely to the pharmacological aspects of anti-aging medicine. It provides a comprehensive overview

of current research aimed to search for natural and synthetic compounds that can potentially be developed as drugs for treating aging-related chronic pathologies and, ultimately, for healthy life extension. In the first section of the book, the basic conceptual and methodological aspects of modern anti-aging medicine are described. The next sections are concerned with the main classes of lifespan-promoting agents, such as antioxidants, calorie restriction mimetics, epigenome-targeted drugs and phytochemicals with health-promoting properties. In the subsequent sections, the strategies for translation of research findings in the field of anti-aging medicine into clinical and healthcare practice as well as opportunities and challenges related to the implementation of such approaches are discussed. This volume constitutes a comprehensive collection of chapters written by leading experts in the field. It will be a relevant and useful resource not only for professional scientists and clinicians, but also for scientifically interested amateurs wishing to know more about the current research in anti-aging pharmacology.

Finally, I would like to acknowledge Dr Oksana Zabuga for the helpful assistance in preparing the manuscript of this volume, as well as the editorial staff at the Royal Society of Chemistry, especially Harriet Manning and Rowan Frame, with whom I had the good fortune to work on this project, for their patience and encouragement.

Alexander M. Vaiserman

Contents

Section I: Overview

Chapter 1	Anti-Aging Drugs: Where are We and Where are We Going?	3
	<i>Alexander M. Vaiserman and Oleh V. Lushchak</i>	
1.1	Introduction	3
1.2	Human Life Extension: Concerns and Considerations	4
1.3	Anti-Aging Pharmacology: Promises and Pitfalls	5
1.4	Concluding Remarks and Future Directions	8
	References	9
Chapter 2	Aging: Natural or Disease? A View from Medical Textbooks	11
	<i>S. Janac, B. Clarke and D. Gems</i>	
2.1	Introduction	11
2.1.1	What Does “Aging” Mean?	12
2.1.2	Is Aging a Disease?	12
2.1.3	What is an Anti-Aging Intervention?	14
2.1.4	Aims of this Study: How is the Aging vs. Disease Division Represented in Medical Textbooks?	15
2.2	How is Aging Viewed in the Medical Field?	17
2.2.1	Two Surveys of the Medical Perception of Aging	17
2.2.2	Medical Textbook Analysis	18
2.3	Discussion	30
	Acknowledgements	32
	References	32

Chapter 3	The Search for the “Anti-Aging Pill”: A Critical Viewpoint	35
	<i>Éric le Bourg</i>	
3.1	Introduction	35
3.2	Diverse Life-History Strategies: Consequences for Lifespan Modulation	37
3.2.1	There Are Various Life-History Strategies in Mammals	37
3.2.2	The Life-History Strategy of the Nematode <i>Caenorhabditis Elegans</i> Could Explain Why Its Longevity is Plastic	41
3.3	Toxic and Essential Molecules May Have the Same Effects at Low Doses	42
3.4	A Drug Treating an Age-Related Pathology is not an “Anti-Aging” Drug	45
3.5	Conclusions	45
	References	47

Section II: Basic Concepts, Models and Approaches

Chapter 4	Testing of Geroprotectors in Experiments on Cell Cultures: Pros and Cons	53
	<i>Alexander N. Khokhlov and Galina V. Morgunova</i>	
4.1	Introduction	53
4.2	Cytogerontological Model Systems	55
4.3	Constructing of Survival Curves for Cultured Cells in Cytogerontological Experiments	58
4.4	Interpretation of Data About the Impact of Geroprotectors on Viability of Cultured Cells in Cytogerontological Studies	63
4.5	Some Words About Biomarkers of Cell Aging/Senescence	65
4.6	Conclusions	68
	References	70
Chapter 5	Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development	75
	<i>Ramón Cacabelos, Juan Carlos Carril and Oscar Teijido</i>	
5.1	Introduction	75
5.2	Age-Related Pheno-Genotypes	76
5.2.1	Age- and Genotype-Related Phenotype Variation in Common Biochemical and Hematological Parameters	78

5.2.2 Common Genes with Age-Related Influence on Health Conditions in NDDs	79
5.3 Pharmacogenomics	83
5.3.1 APOE-TOMM40	95
5.3.2 CYPs	97
5.3.3 Transporters	99
5.4 Epigenomics	100
5.4.1 Age-Related Epigenetics	101
5.4.2 Neurodegenerative Disorders	103
5.5 Pharmacoeugenomics	108
5.6 Novel Strategies	111
5.6.1 LipoFishins	123
5.6.2 Atremorine (E-PodoFavalin-15999)	126
5.7 Future Trends for the Management of Age-Related NDDs	129
Acknowledgements	131
References	131
Chapter 6 Nanotechnology in Anti-Aging: Nutraceutical Delivery and Related Applications	142
<i>Anila Mathew, Francesco Marotta and D. Sakthi Kumar</i>	
6.1 Introduction	142
6.2 Nutraceuticals and Nanodevelopments	143
6.3 Nanoformulations of Bioactive Compounds	146
6.3.1 Nanoemulsions	147
6.3.2 Nanoencapsulation/Nanoparticles	154
6.3.3 Liposomes	157
6.3.4 Other Nanoformulation Strategies: Nanodisks, Nanogels, Nanofibers <i>etc.</i>	157
6.4 Safety and Regulatory Aspects of Nanofoods	159
6.5 Consumer Attitude Towards Nanotechnology in Food-Related Applications	162
6.6 Conclusion	163
References	164
Chapter 7 Hormetins as Drugs for Healthy Aging	170
<i>Suresh I. S. Rattan</i>	
7.1 Introduction	170
7.2 Aging in a Nutshell	171
7.3 Hormesis and Stress Response	172
7.4 Hormetins for Health and Longevity	174
7.5 Discovering Novel Hormetins	175
7.6 Drugs for Health and Longevity	176
References	177

Section III: Antioxidants

Chapter 8	Antioxidant Therapy of Aging: From Free Radical Chemistry to Systems Theory of Reliability	183
	<i>V. K. Koltover</i>	
8.1	Introduction: Historical Synopsis	183
8.2	Aging <i>Versus</i> Reliability	184
8.2.1	Theory of Reliability: Basic Ideas	184
8.2.2	Preset Reliability Prescribes Lifespan	185
8.3	Free-Radical Failures	187
8.3.1	Free-Radical Malfunctions of Electron-Transport Nanoreactors	187
8.3.2	Free-Radical Redox-Timer of Aging	189
8.4	Extension of Lifespan by Antioxidants	191
8.4.1	Antioxidants: Radical Chemistry Standpoint	191
8.4.2	Antioxidants: Reliability-Theory Standpoint	195
8.5	Conclusions	200
	Acknowledgements	200
	References	201
Chapter 9	Mitochondria-Targeted Rechargeable Antioxidants as Potential Anti-Aging Drugs	205
	<i>Elena G. Pasyukova, Boris A. Feniouk and Vladimir P. Skulachev</i>	
9.1	Introduction	205
9.2	Mitochondria Malfunction and Aging	206
9.3	The Link Between Oxidative Stress and Aging	207
9.4	Mitochondria-Targeted Rechargeable Antioxidants	209
9.4.1	Mitochondria-Targeted Antioxidants in Invertebrate Models	211
9.4.2	SkQ1 Affects Early Survival and Aging in Unmated Flies	212
9.4.3	SkQ1 Affects Reproduction in Mated Flies	213
9.4.4	SkQ1 Acts as a Mitochondria-Targeted Antioxidant Combating ROS in <i>D. melanogaster</i>	214
9.4.5	SkQ1 Effects are Stable Under Different Experimental Scenarios and Across Different Wild-Type Genotypes	216
9.5	Mitochondria-Targeted Antioxidants in Rodents	218
9.6	Conclusion	220
	Acknowledgements	220
	References	220

Section IV: Mimicking Caloric Restriction

Chapter 10	Mimetics of Caloric Restriction	231
	<i>Oleh Lushchak and Dmytro Gospodaryov</i>	
10.1	Introduction	231
10.2	Aging and CR	233
10.2.1	CR in Yeast: <i>Saccharomyces cerevisiae</i>	233
10.2.2	CR in Worms: <i>Caenorhabditis elegans</i>	234
10.2.3	CR in Fruit Flies	235
10.2.4	CR in Mammals	236
10.3	Beneficial Effects of CR	238
10.3.1	Cardiovascular System	238
10.3.2	Brain Function	239
10.3.3	Hormonal Regulation	240
10.4	Intracellular Consequences of CR	241
10.4.1	Autophagy	242
10.4.2	Metabolism of Reactive Oxygen Species	243
10.5	Ways to Achieve CR	244
10.5.1	Decreased Food Consumption	244
10.5.2	Dietary Composition	245
10.5.3	Inhibition of Food Digestion and Absorption	245
10.5.4	Decrease in Appetite and Satiety	246
10.5.5	Mimetics of CR	246
10.6	Intracellular Targets of CR	249
10.6.1	Sensors of Nutrient and Energy State	249
10.6.2	Signaling Pathways	250
10.7	Conclusion	255
	Acknowledgements	257
	References	257
Chapter 11	Allosteric SIRT1 Activators as Putative Anti-Aging Drugs	272
	<i>Basil P. Hubbard</i>	
11.1	Introduction	272
11.2	The Sirtuin Longevity Pathway	273
11.3	Small-Molecule SIRT1 Activators	275
11.4	STACs in Aging and Age-Related Disease	278
11.4.1	Lifespan Extension	278
11.4.2	Obesity, Metabolism, and Type II Diabetes	280
11.4.3	Cancer	281
11.4.4	Neurodegenerative Disease	282
11.4.5	Cardiovascular Disease	282
11.4.6	Inflammation and Immunity	283
11.4.7	Fertility and Development	284

11.5 Clinical Challenges with STACs	285
11.5.1 Pharmacology	285
11.5.2 Regulatory Paradigms	286
11.6 Conclusion	287
References	287
Chapter 12 Therapeutic Potential of Sirtuin Inhibitors in Cancer	298
<i>Francisco Javier Alcaín, Consuelo M. Nieva, Lucía Fernández del Río, Raquel Santiago-Mora, Elena Gutiérrez-Casado, Mario Duran-Prado and Jose M. Villalba</i>	
12.1 Introduction	298
12.2 Expression of Sirtuins in Cancer Cells	299
12.3 Sirtuins and the Hallmarks of Cancer	301
12.4 Sirtuin Inhibitors as Anticancer Agents	306
12.4.1 Nicotidamine and Its Analogues	306
12.4.2 Splitomicin and Its Derivatives	308
12.4.3 Sirtinol	309
12.4.4 Cambinol	310
12.4.5 Salermide	313
12.4.6 Indole Derivatives	313
12.4.7 Tenovin	314
12.4.8 Other Inhibitors of Human Sirtuins	317
12.5 Concluding Remarks	319
Acknowledgements	319
References	319
Chapter 13 Lifespan-Extending Effect of Resveratrol and Other Phytochemicals	328
<i>Shin-Hae Lee and Kyung-Jin Min</i>	
13.1 Introduction	328
13.2 Resveratrol	329
13.2.1 Lifespan-Extending Effect of Resveratrol in Invertebrates: Yeasts, Worms and Flies	329
13.2.2 Lifespan-Extending Effects of Resveratrol in Vertebrate: Fishes and Rodents	331
13.2.3 Clinical Trials of Resveratrol in Human Subjects	332
13.2.4 Putative Target Molecules for Lifespan-Extending Effect of Resveratrol	333
13.2.5 Uncertainty of Resveratrol as a Clinical Drug	336
13.3 Other Phytochemicals with Lifespan-Extending Effects	337
13.3.1 Curcumin	337

<i>Contents</i>		xvii
	13.3.2 Quercetin	339
	13.3.3 Catechin	339
	13.3.4 Others	340
	13.4 Conclusion	342
	References	342
Chapter 14	Extending Lifespan by Inhibiting the Mechanistic Target of Rapamycin (mTOR)	352
	<i>Dudley W. Lamming</i>	
	14.1 The Discovery of Rapamycin and mTOR	352
	14.2 mTOR Regulates Longevity in Model Organisms	354
	14.3 Rapamycin Extends the Lifespan and Healthspan of Mice	355
	14.4 How Does Rapamycin Increase Longevity?	358
	14.5 Side Effects of Rapamycin Treatment—The Role of mTORC2	359
	14.6 mTORC1 Is a Key Integrator of Nutrient and Hormonal Signaling	360
	14.7 How Can mTORC1 Be Specifically Targeted?	362
	14.8 Conclusions	365
	Acknowledgements	365
	References	366
Chapter 15	mTOR, Aging and Cancer: Prospects for Pharmacological Interventions	376
	<i>Z. D. Sharp</i>	
	15.1 Rapamycin: A Brief History	376
	15.2 The Target of Rapamycin	377
	15.3 Rapamycin's Mysterious Effects on Aging	379
	15.4 Effects of Chronic Rapamycin on Age-Associated Diseases	379
	15.5 TOR Reductions and Rapamycin Increase Longevity in Other Organisms	382
	15.6 Genetic mTOR Inhibition in Mice that Extends Life Span	383
	15.7 Composite Picture of mTOR Signaling Pathways in Aging	383
	15.8 Why This Is Important	385
	15.9 Summary	386
	Potential Financial Conflict of Interest	387
	Acknowledgements	387
	References	387

Chapter 16	Anti-Aging Action of PPARs: Potential Therapeutic Targets	393
	<i>Ki Wung Chung, Byung Pal Yu and Hae Young Chung</i>	
16.1	Introduction	393
16.2	Age-Related Changes in Inflammation and Their Role in Metabolic Diseases	394
16.2.1	Chronic Inflammation and Aging	394
16.2.2	Roles of Inflammation in Metabolic Diseases During Aging	395
16.3	Functions of PPARs in the Regulation of Metabolism and Inflammation	396
16.3.1	PPAR Signaling and Metabolism	396
16.3.2	PPARs and Inflammation	398
16.4	Evidence for Involvement of PPARs in Age-Related Inflammatory Diseases and Aging	400
16.4.1	The Role of PPARs in Age-Related Inflammatory Diseases	401
16.4.2	PPARs in Aging and Longevity	403
16.5	Anti-Aging and Therapeutic Potentials of New PPAR Agonists	404
16.6	Effects of Anti-Aging Calorie Restriction on PPAR Modulation	406
16.7	Conclusion	407
	References	408
Chapter 17	Antidiabetic Biguanides as Anti-Aging Drugs	416
	<i>Vladimir N. Anisimov</i>	
17.1	Introduction	416
17.2	Milestones in Research on Biguanides as Drugs for Aging Prevention in Rodents	417
17.3	Effect of Antidiabetic Biguanides on Aging and Life Span in Rats	418
17.4	Effect of Antidiabetic Biguanides on Aging and Life Span in Mice	420
17.5	Antidiabetic Biguanides in Prevention of Age-Associated Diseases in Mouse Models	424
17.6	Antidiabetic Biguanides as Anti-Carcinogens and Inhibitors of Tumor Growth in Rodents	424
17.7	Conclusion	427
	Acknowledgement	429
	References	429

Section V: Other Pharmacological Approaches

Chapter 18	<i>S</i>-Adenosylmethionine Metabolism: A Promising Avenue in Anti-Aging Medicine?	435
	<i>W. A. M. Loenen</i>	
18.1	Introduction	435
18.1.1	Discovery of <i>S</i> -Adenosylmethionine	435
18.1.2	SAM and Aging	436
18.1.3	This Review	437
18.2	SAM-Dependent Enzymes	437
18.2.1	Parts of SAM Used by SAM-Dependent Enzymes	437
18.2.2	Structures of SAM-Dependent Enzymes	438
18.3	Well-Known Pathways of SAM in Central Metabolism	438
18.3.1	The Methionine Cycle	438
18.3.2	The Transsulfuration Pathway to Glutathione	442
18.3.3	The Polyamine Pathway	442
18.4	SAM and RNA-Based Control by Riboswitches	443
18.4.1	Discovery of SAM Riboswitches	443
18.4.2	SAM and Other Riboswitches	443
18.5	'Radical SAM' Proteins with Iron–Sulfur (FeS) Clusters	444
18.5.1	Discovery of Radical SAM Enzymes	444
18.5.2	The Radical SAM-Binding Domain	444
18.5.3	Types of SAM Radical Enzymes	445
18.5.4	Radical SAM Methyltransferases (RSMT)	446
18.5.5	Radical SAM Methylthiotransferases (MMTases)	447
18.5.6	The Special Case of Elp3	447
18.5.7	Lessons from SAM-Independent FeS Proteins?	448
18.6	SAM and Aging	449
18.6.1	SAM, Mitochondria and Aging	449
18.6.2	SAM and Neurodegeneration	449
18.6.3	SAM and Long-Lived Rodents	450
18.6.4	SAM, the Microbiome and Aging	450
18.6.5	SAM and Establishment and Maintenance of the Microbiome	451
18.7	Conclusions	452
	Note Added after Completion of the Manuscript	453
	Abbreviations	453
	References	454

Chapter 19	Melatonin as a Geroprotector: Healthy Aging vs. Extension of Lifespan	474
	<i>R. Hardeland</i>	
19.1	Introduction	474
19.2	Overview of Melatonin's Actions in Relation to Aging	477
19.2.1	Energy Balance and Metabolic Sensing	477
19.2.2	Counter-Action of Mitochondrial Dysfunction and Anti-Oxidant Actions	481
19.2.3	Immunological Actions and Prevention of Inflammaging	483
19.2.4	Telomere Attrition	486
19.3	Lifespan, Health, Deceleration and Deacceleration of Aging	486
19.4	Conclusion	488
	References	489
Chapter 20	Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span	496
	<i>Vladimir Khavinson and Irina Popovich</i>	
20.1	Introduction	496
20.2	Isolated Peptide Complexes	498
20.3	Short Synthetic Peptides	500
20.4	Influence of Short Peptides on Immune and Antioxidant Systems	501
20.5	The Influence of Short Peptides on Gene Expression	503
20.6	Application of Peptide Bioregulators in Elderly Patients	504
20.7	Prospective Cellular and Molecular Mechanism of Action of Short Peptides	507
20.8	Conclusion	509
	References	510
Chapter 21	HDAC Inhibitors: A New Avenue in Anti-Aging Medicine	514
	<i>E. G. Pasyukova and A. M. Vaiserman</i>	
21.1	Introduction	514
21.2	Role of Histone Modification in Epigenetic Regulation	516
21.3	Life Span-Modulating Effects of HDAC Inhibitors in Animal Models	517
21.3.1	Phenylbutyrate	518
21.3.2	Sodium Butyrate	519
21.3.3	Trichostatin A	523
21.3.4	Suberoylanilide Hydroxamic Acid (SAHA)	525

<i>Contents</i>	xxi
21.4 HDACIs in Preclinical and Clinical Trials	526
21.4.1 Cancer	527
21.4.2 Metabolic and Cardiovascular Pathology	527
21.4.3 Neurodegenerative Diseases	528
21.4.4 Inflammatory Disorders	528
21.5 Conclusion	529
Acknowledgements	529
References	529

Section VI: Social Context

Chapter 22 Human Life Extension: Opportunities, Challenges, and Implications for Public Health Policy	537
<i>Ilia Stambler</i>	
22.1 Introduction: The Diverse Aspects of Life Extension Promotion as a Part of Health Promotion	537
22.2 Scientific and Technological Implications and Challenges: Is Human Life Extension Scientifically and Technologically Feasible?	540
22.3 Implications and Challenges for the Individual and the Society: Is Life Extension a Desirable Goal?	545
22.4 Normative Action: What Should We Do?	551
22.4.1 Funding	552
22.4.2 Incentives	554
22.4.3 Institutional Support	557
References	559
Subject Index	565

Section I

Overview

Anti-Aging Drugs: Where are We and Where are We Going?

ALEXANDER M. VAISERMAN*^a AND OLEH V. LUSHCHAK^b

^aLaboratory of Epigenetics, Institute of Gerontology, Kiev, Ukraine;

^bDepartment of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, Ivano-Frankivsk, Ukraine

*E-mail: vaiserman@geront.kiev.ua

1.1 Introduction

Human longevity dramatically increased during the last century when implementation of vaccinations, disinfectants and antibiotics led to a substantial reduction of infectious diseases as a leading cause of death.¹ The decline in mortality among the elderly has continued over the past few decades. It is most probably owing to preventative factors, such as improved diets, as well as exercise and reduction in smoking.² If current demographic trends continue then 20% percent of the global population of 9 billion will be over the age of 60 by 2050.³ As a consequence, most modern nations are undergoing rapid population aging. Although the life expectancy has enhanced dramatically in modern generations, this process has, nevertheless, not been accompanied by an equivalent increase in healthy life expectancy.⁴ Since aging is a primary risk factor in most chronic disorders, the prevalence of age-associated disorders, such as type 2 diabetes, neurodegenerative disease, cardiovascular disease, osteoporosis and cancer, rises considerably with the increasing average age in populations of developed countries, representing a

great socio-economic challenge. It is estimated that there will be more than 30 million people over the age of 80 will be in the U.S. by 2050; about half of them will suffer from different forms of dementia, and at least 3 million of all adults will be diagnosed with Parkinson's disease.⁵ The expected prevalence of age-associated conditions will have substantial consequences for future society, including increased financial and psychological burdens for families and greater pressure on government health care programs and entitlement budgets.^{6,7} The demographic trend consisting of an increasing proportion of aged people in the populations of developed countries likely explains the dramatic increase in the interest of the lay public and country leaders in research in the field of biogerontology.⁸

1.2 Human Life Extension: Concerns and Considerations

Investigations aimed at human life extension have traditionally raised concerns that it can lead to the growth of the older population segment and, consequently, to the high prevalence of ageing-associated chronic pathologies. Numerous experimental studies have, however, demonstrated that life extension is usually accompanied by delayed or reduced morbidity, including cardiovascular disease, neurodegeneration, and tumors.⁹ There is also increasing evidence from epidemiological studies, which is consistent with the findings from animal models. For example, centenarians, in particular those who live in so-called 'Blue Zones' (five regions in Europe, Latin America, Asia and the US with unusually high concentrations of centenarians), have been not only shown to exhibit exceptional longevity but also often remain free from disability and chronic diseases until very advanced age.¹⁰

The compression of morbidity has been the primary strategy in gerontology and geriatric research during the last few decades. This strategy claims that we may limit morbidity to a shorter period closer to the natural ending of life, thus reducing the burden of illness and disability by delaying the age at onset of major age-associated chronic disorders.¹¹ Geroscience, a novel branch of geriatric medicine, is centered on healthspan extension.¹² Extension of healthspan is a crucial component of achieving 'optimal longevity', defined as living long, but with good health and quality of life, including improved functioning, productivity and independence.¹¹ Attempts to increase healthspan are currently focused on slowing the basic biological processes accompanying aging, such as mitochondrial dysfunction, cellular senescence, age-related decline of stress resistance, dysregulated cellular energy sensing and growth pathways, impaired proteostasis, deteriorated stem cell function/bioavailability, as well as oxidative and inflammation stress.^{13,14} All these processes interfere with the normal physiological cellular signaling pathways, demanding compensatory adjustments with aging to maintain homeostasis. At a certain age, however, these compensatory mechanisms become exhausted and different aspects of aging are manifested,

thereby increasing the risk for functional decline and the onset and progression of chronic diseases.¹⁵ Therapeutic strategies to combat aging and age-related diseases are a part of an investigation field commonly referred to as ‘anti-aging medicine’. Anti-aging medicine has emerged as a new specialization in medical practice at the beginning of the 1990s. Over the past few years, it has become an increasingly discussed and debated topic.¹⁶ Its main purpose is to prolong both healthspan and lifespan by specific regimes of exercise and dieting, as well as by advanced biomedical interventions aimed at slowing, stopping or reversing the aging process.^{17,18}

Traditionally, the process of aging is believed to be ‘natural’ and therefore inevitable. However, in the view of many authors, the idea that aging is an infeasible part of human nature is quite questionable.¹⁹ In accordance with many modern evolutionary theories, aging has emerged as a by-product of evolutionary processes and does not have a specific function.²⁰ If aging is really not an intrinsic, irrevocable component of life, then it could be manipulated similarly to other processes that are generally deemed to be unnatural or pathological. The major assumption underlying anti-aging research is that age-associated senescence may be regarded as a pathophysiological phenomenon that might be prevented or even reversed.²¹ Modern anti-aging medicine promotes biomedical technologies and approaches that have the potential to delay or postpone aging processes.² The success obtained in this research field is greatly attributed to the increasingly broad application of omics-based approaches, such as genomics, transcriptomics, proteomics and metabolomics.²² Through the implementation of these technologies, a better understanding has been achieved regarding the key molecular and cellular pathways involved in the aging process, including inflammation, proteostasis, autophagy, mitochondrial efficiency and nutrient signaling, and regarding the most effective interventions to counteract age-related senescence.^{23,24} The impetuous progress in highlighting the mechanisms underlying aging and longevity and first successful pharmacological interventions to extend healthy lifespan in different model organisms indicate that the aging process is malleable.

1.3 Anti-Aging Pharmacology: Promises and Pitfalls

The development of pharmacological agents targeting aging-related functional declines and pathological manifestations (‘anti-aging drugs’) is now in the spotlight in geroscience. An exponential growth of research in the field of geriatric pharmacology, including the study of prospective anti-aging drugs, has been observed over the past 20 years.²⁵ The first step in the process of drug development is known to involve the selection of druggable targets.²⁶ The situation when gene targets are determined by the study of genetic variations linked to either gain-of-function or loss-of-function phenotypes is especially useful because these targets can be considered as those that have been reliably validated.²⁷ Over the last two decades, a number of genetic pathways have been identified that play an unequivocal role in control of the aging

process and longevity;^{28–30} all these genes represent attractive drug targets. Currently, many pharmacological agents targeting the putative mechanisms of aging are under development.

Taking into account the extraordinary complexity of the mechanistic pathways underlying the aging process, the recognition of these pathways and development of anti-aging interventions seems a challenging task. Significant progress has, however, been achieved in the last few years in this research field. A number of pharmacological agents with the potential to target particular aging-associated pathways and to produce protective responses against age-related pathologies are currently under investigation. In recent years, several classes of bioactive chemical agents and nutraceuticals have been shown to have potential therapeutic efficacy in anti-aging medicine.^{3,31} In experimental studies, many substances have been identified as having life-extending properties. Among them are calorie restriction mimetics, such as resveratrol, rapamycin and metformin,^{32,33} antioxidants (vitamins A, C and E, quercetin, melatonin, coenzyme Q10, *etc.*),³⁴ autophagy inductors, such as spermidine,^{35,36} senolytics,³⁷ phytochemicals, *e.g.*, curcumin, genistein, catechins and epigallocatechin gallate (EGCG),³⁸ and several other natural and chemical compounds. In recent years, modern biotechnological approaches have been used for developing novel anti-aging pharmaceutical applications. For example, the coupling of curcumin-based nanoparticles with the Tet-1 peptide, which has affinity for neurons and possess retrograde transportation properties,³⁹ as well as mitochondria-targeted antioxidant SkQ1,⁴⁰ have been recently explored as promising therapeutic applications for the treatment of Alzheimer's disease. Over the last decade, consistent evidence has also been reported for the role of epigenetic factors, including DNA methylation, histone modifications and microRNA regulation, in the aging process as well as in the pathogenesis and progression of age-related diseases.^{41,42} A lot of hope is being pinned, therefore, on pharmacological agents targeted to the epigenetic regulation of gene activity, such as inhibitors of DNA methyltransferases and histone deacetylases, including sodium butyrate, trichostatin A, sodium 4-phenylbutyrate and suberoylanilide hydroxamic acid.⁴³

It should, however, be noted that all agents that can be classified as potent anti-aging therapeutic compounds are multi-functional and targeted at multiple signaling pathways mediating aging. Moreover, the evidence remains limited regarding the overall health benefits of these substances, including epidemiological studies exploring the consequences of their long-term intake for human health. Furthermore, there is evidence that uncontrolled intake of some anti-aging agents can be useless or even harmful. For example, the consumption of antioxidants is considered as quite reasonable by many researchers, especially in the cardiovascular research area.⁴⁴ The appropriateness of antioxidant intake, however, still remains a matter of debate. Meta-analysis of observational studies and randomized controlled trials conducted in well-nourished and healthy populations demonstrated that antioxidant supplementation may be associated with undesirable consequences for health and all-cause mortality.⁴⁵ Another example is the fact that supplementation with several promising pro-healthspan compounds can

in some cases trigger insulin resistance. This applies to substances such as rapamycin⁴⁶ and statins.⁴⁷ Therefore, people should use them with caution and only with careful medical monitoring.

Another method of anti-aging drug discovery is evaluating the pharmacological agents already approved by the FDA and other regulatory agencies for treatment of particular conditions associated with aging, such as statins, metformin, beta-blockers, renin-angiotensin-aldosterone system inhibitors, thiazolidinediones, and anti-inflammatory medications.⁴⁸ These classes of drugs are commonly used in the treatment of patients with various chronic medical conditions and their efficacy and safety have been proven in many clinical trials. They have also been shown to improve health, physiological functioning and well-being in middle to old age patients with chronic disorders.⁴⁹ Such agents are presently not used in the treatment of age-associated physiological dysfunctions in the absence of clinical manifestation of disease. However, these medications might theoretically be redirected to treating or preventing conditions or syndromes typically associated with aging.

Le Couteur *et al.*⁵⁰ noted in their review that 'despite the potential profits and the extraordinary capacity of drug discovery technology, there is a paucity of new drugs in the development pipeline, particularly for those medications that are likely to be highly profitable because they are used long term and by a large proportion of the population.' The longevity dividend, *i.e.* an idea that extending healthy life by slowing aging is the most efficient way to combat the fatal and disabling pathologies that plague us today,⁵¹ may provide an opportunity to revitalize the drug development pipeline. Indeed, by delaying the aging process *per se*, it likely would be possible to prevent or delay all age-associated pathologies rather than to overcome them one by one, which is the current approach of the disease-based paradigm in drug development. Furthermore, prevention of a particular age-related chronic disorder, *e.g.*, cardiovascular disease, will apparently have only a modest effect on the population life expectancy because comorbidity, *e.g.*, cancer, will to a great extent substitute the reduction in mortality risk caused by preventing the targeted pathology. The main idea of geroscience is that preventing the clinical manifestations of all age-related diseases as a group by inhibiting the basic aging mechanisms can be far more effective than preventing the individual chronic disorders.^{11,49} A recent analysis conducted by Goldman *et al.*⁵² demonstrated that substantial socio-economic benefits might be derived from this approach in comparison with current public health strategy targeted to prevention of particular disorders. According to this analysis, the economic impact of delaying aging and increasing healthspan in the US is estimated at ~7 trillion dollars over the next fifty years. Hence, it is obvious that discovery of new drug targets based on biogerontological research represents an incredible opportunity for the pharmaceutical and healthcare industries.⁵³ Currently, the consensus among physicians and health professionals that the optimization of physiological and mental functioning throughout the life course should be a major emphasis of any contemporaneous biomedical policy addressing global aging. A healthy lifestyle comprising proper

nutrition and physical activity represents the first-line function-preserving strategy. Pharmacological compounds, both existing and potential, can serve as a prospective complementary approach.⁴⁸

1.4 Concluding Remarks and Future Directions

To summarize, it can be assumed that targeting aging *per se* can be a more effective approach to postponing or preventing age-related disorders than treatments targeted to specific pathological conditions. Because of the aging population, such a therapeutic strategy is undoubtedly an area of increasing relevance for the pharmaceutical industry and public health organizations. As has been recently emphasized by Longo *et al.*,⁵⁴ ‘the time has come not only to consider several therapeutic options for the treatment of age-related comorbidities, but to initiate clinical trials with the ultimate goal of increasing the healthspan (and perhaps longevity) of human populations, while respecting the guiding principle of physicians *primum non nocere*.’ In modern pharmacy, anti-aging is likely one of the most prospective markets because the target group can potentially include each person. Several supplements, such as resveratrol, are already advertised in the pharmaceutical market as “anti-aging pills”.⁵⁵ Very promising in this regard is rapamycin (also known as sirolimus), which is already approved by the FDA as an anti-biotic and immunosuppressant drug. Current marketing research demonstrates that most people are willing to pay for long-term pharmacological therapy to prevent or delay the aging-related decline in physical and mental functions.⁵⁰ Recent sociological surveys show a great desire for extended life and health in the US and worldwide. In most of the surveys conducted until now, the cautious attitude to life extension was a consequence of an erroneous equation of extended life with a prolonged period of age-related functional decline and frailty. When continued health was stipulated in the questionnaire design, responses significantly favored longer life. In the survey by Donner *et al.*,⁵⁶ 20% of respondents wished to die at the age of 85, whereas 42% wanted to have an unlimited lifespan. Despite the widespread misconception that implementation of anti-aging medicine would increase the proportion of chronic patients in modern societies, it in fact would lead to reducing the ratio of unhealthy to healthy population since it would result in delaying the onset of age-related pathological conditions. In other words, it may lead to a decrease of biological age (*i.e.*, old individuals will become biologically younger) and to an increase of the age of disability, thereby increasing the retirement age and enhancing revenues without enhancing taxes.⁵⁷ Optimistic predictions of the feasibility of health- and life-extending interventions, however, should certainly be critically discussed in terms of their ethical, economic and social implications. Only after in-depth examination and following comprehensive debates will the implementation of such approaches in clinical practice be possible.

References

1. J. P. de Magalhães, *Rejuvenation Res.*, 2014, **17**, 458.
2. J. Vijg and A. D. de Grey, *Gerontology*, 2014, **60**, 373.
3. B. K. Kennedy and J. K. Pennypacker, *Transl. Res.*, 2014, **163**, 456.
4. W. W. Hung, J. S. Ross, K. S. Boockvar and A. L. Siu, *BMC Geriatr.*, 2011, **11**, 47.
5. G. A. Petsko, *Genome Biol.*, 2008, **9**, 113.
6. S. Harper, *Science*, 2014, **346**, 587.
7. J. R. Beard and D. E. Bloom, *Lancet*, 2015, **385**, 658.
8. E. Le Bourg, *Biogerontology*, 2013, **14**, 221.
9. L. Fontana, L. Partridge and V. D. Longo, *Science*, 2010, **328**, 321.
10. B. J. Willcox, D. C. Willcox and L. Ferrucci, *J. Gerontol., Ser. A*, 2008, **63**, 1181.
11. D. R. Seals, R. E. Kaplon, R. A. Gioscia-Ryan and T. J. LaRocca, *Physiology*, 2014, **29**, 250.
12. B. K. Kennedy, S. L. Berger, A. Brunet, J. Campisi, A. M. Cuervo, E. S. Epel, C. Franceschi, G. J. Lithgow, R. I. Morimoto, J. E. Pessin, T. A. Rando, A. Richardson and E. E. Schadt, *et al.*, *Cell*, 2014, **159**, 709.
13. J. L. Kirkland, *Exp. Gerontol.*, 2013, **48**, 1.
14. L. Fontana, B. K. Kennedy, V. D. Longo, D. Seals and S. Melov, *Nature*, 2014, **511**, 405.
15. E. S. Epel and G. J. Lithgow, *J. Gerontol., Ser. A*, 2014, **69**, S10.
16. G. Barazzetti and M. Reichlin, *Swiss Med. Wkly.*, 2011, **141**, w13181.
17. R. Klatz, *Ann. N. Y. Acad. Sci.*, 2005, **1057**, 536.
18. M. Tosato, V. Zamboni, A. Ferrini and M. Cesari, *Clin. Interventions Aging*, 2007, **2**, 401.
19. A. L. Caplan, in *The Fountain of Youth. Cultural, Scientific, and Ethical Perspectives on a Biomedical Goal*, ed. S. G. Post and R. H. Binstock, Oxford University Press, Oxford, 2004, pp. 271–285.
20. J. F. Lemaitre, V. Berger, C. Bonenfant, M. Douhard, M. Gamelon, F. Plard and J. M. Gaillard, *Proc. Biol. Sci.*, 2015, **282**, 2015020.
21. B. Anton, L. Vitetta, F. Cortizo and A. Sali, *Ann. N. Y. Acad. Sci.*, 2005, **1057**, 525.
22. E. Cevenini, E. Bellavista, P. Tieri, G. Castellani, F. Lescai, M. Francesconi, M. Mishto, A. Santoro, S. Valensin, S. Salvioli, M. Capri, A. Zaikin and D. Monti, *et al.*, *Curr. Pharm. Des.*, 2010, **16**, 802.
23. R. de Cabo, D. Carmona-Gutierrez, M. Bernier, M. N. Hall and F. Madeo, *Cell*, 2014, **157**, 1515.
24. E. K. Quarles, D. F. Dai, A. Tocchi, N. Basisty, L. Gitari and P. S. Rabinovitch, *Ageing Res. Rev.*, 2015, **23**, 101.
25. E. Verdaguer, F. Junyent, J. Folch, C. Beas-Zarate, C. Auladell, M. Pallàs and A. Camins, *Expert Opin. Drug Discovery*, 2012, **7**, 217.
26. Y. Zhou and N. Huang, *Methods Mol. Biol.*, 2015, **1289**, 13.
27. S. M. Paul, D. S. Mytelka, C. T. Dunwiddie, C. C. Persinger, B. H. Munos, S. R. Lindborg and A. L. Schacht, *Nat. Rev. Drug Discovery*, 2010, **9**, 203.

28. A. A. Moskalev, A. M. Aliper, Z. Smit-McBride, A. Buzdin and A. Zhavoronkov, *Cell Cycle*, 2014, **13**, 1063.
29. C. M. Lindborg, K. J. Property and R. J. Pignolo, *Mech. Ageing Dev.*, 2015, **146–148**, 23.
30. A. H. Shadyab and A. Z. LaCroix, *Ageing Res. Rev.*, 2015, **19**, 1.
31. M. V. Blagosklonny, *Cell Death Discovery*, 2014, **5**, e1552.
32. G. Testa, F. Biasi, G. Poli and E. Chiarpotto, *Curr. Pharm. Des.*, 2014, **20**, 2950.
33. D. K. Ingram and G. S. Roth, *Ageing Res. Rev.*, 2015, **20**, 46.
34. M. Wojcik, I. Burzynska-Pedziwiatr and L. A. Wozniak, *Curr. Med. Chem.*, 2010, **17**, 3262.
35. N. Minois, *Gerontology*, 2014, **60**, 319.
36. F. Madeo, A. Zimmermann, M. C. Maiuri and G. Kroemer, *J. Clin. Invest.*, 2015, **125**, 85.
37. M. Malavolta, E. Pierpaoli, R. Giacconi, L. Costarelli, F. Piacenza, A. Basso, M. Cardelli and M. Provinciali, *Curr. Drug Targets*, 2016, **17**, 447.
38. H. Si and D. Liu, *J. Nutr. Biochem.*, 2014, **25**, 581.
39. A. Mathew, T. Fukuda, Y. Nagaoka, T. Hasumura, H. Morimoto, Y. Yoshida, T. Maekawa, K. Venugopal and D. S. Kumar, *PLoS One*, 2012, **7**, e32616.
40. N. A. Stefanova, N. A. Muraleva, V. P. Skulachev and N. G. Kolosova, *J. Alzheimers Dis.*, 2014, **38**, 681.
41. A. Brunet and S. L. Berger, *J. Gerontol., Ser. A*, 2014, **69**, S17.
42. D. Ben-Avraham, *Adv. Exp. Med. Biol.*, 2015, **847**, 179.
43. A. M. Vaiserman and E. G. Pasyukova, *Front. Genet.*, 2012, **3**, 224.
44. U. Alehagen, J. Aaseth and P. Johansson, *PLoS One*, 2015, **10**, e0141641.
45. G. Bjelakovic, D. Nikolova and C. Gluud, *Curr. Opin. Clin. Nutr. Metab. Care*, 2014, **17**, 40.
46. M. V. Blagosklonny, *Aging (Albany NY)*, 2012a, **4**, 350.
47. B. D. Henriksbo and J. D. Schertzer, *Adipocyte*, 2015, **4**, 232.
48. D. R. Seals, J. N. Justice and T. J. LaRocca, *J. Physiol.*, 2016, **594**, 2001.
49. D. R. Seals and S. Melov, *Aging (Albany NY)*, 2014, **6**, 718.
50. D. G. Le Couteur, A. J. McLachlan, R. J. Quinn, S. J. Simpson and R. de Cabo, *J. Gerontol., Ser. A*, 2012, **67A**, 168.
51. S. J. Olshansky, *Public Policy Aging Rep.*, 2013, **23**, 3.
52. D. P. Goldman, D. Cutler, J. W. Rowe, P. C. Michaud, J. Sullivan, D. Peneva and S. J. Olshansky, *Health Aff.*, 2013, **32**, 1698.
53. D. G. Le Couteur and D. A. Sinclair, *J. Gerontol., Ser. A*, 2010, **65**, 693.
54. V. D. Longo, A. Antebi, A. Bartke, N. Barzilai, H. M. Brown-Borg, C. Caruso, T. J. Curiel, R. de Cabo, C. Franceschi, D. Gems, D. K. Ingram, T. E. Johnson and B. K. Kennedy, *et al.*, *Aging Cell*, 2015, **14**, 497.
55. J. Aschemann-Witzel and K. G. Grunert, *Ann. N. Y. Acad. Sci.*, 2015, **1348**, 171.
56. Y. Donner, K. Fortney, S. R. Calimport, K. Pflieger, M. Shah and J. Betts-LaCroix, *Front. Genet.*, 2015, **6**, 353.
57. M. V. Blagosklonny, *Aging (Albany NY)*, 2012b, **4**, 547.

Aging: Natural or Disease? A View from Medical Textbooks

S. JANAC^a, B. CLARKE^b AND D. GEMS*^a

^aUniversity College London, Institute of Healthy Ageing, Gower Street, London, WC1E 6BT, UK; ^bUniversity College London, Department of Science and Technology Studies, Gower Street, London, WC1E 6BT, UK
*E-mail: david.gems@ucl.ac.uk

2.1 Introduction

Whether a given condition is labelled as a disease or not can depend on a number of factors—including linguistics. For example, in one survey people were asked of 60 different conditions whether they considered them to be a disease or not.¹ The study found that alcoholism was seen as a disease, but smoking not. In some ways this is an odd finding since both—broadly speaking—elicit dependence symptoms, involve substance abuse and are detrimental to health in the long-term. Plausibly, this quirk reflects the choice of words employed in the survey. Perhaps if the terms used had instead been *drinking* and *nicotine addiction*, the classification would have come out the other way around.

Difficulties of classification also affect *aging*. For example, if one went to the doctor and asked for a prescription for anti-aging drugs, their response would likely be surprise, amusement or perhaps mild irritation. This is because aging, in the medical field, is not regarded as a disease.

The question of what exactly is meant by “anti-aging drugs” is complicated by several factors. First, linguistics, and the problem that the word “aging” has more than one meaning. Second, the question of whether aging is a disease. Thirdly, problems relating to what counts as an anti-aging intervention. These issues will be reviewed here briefly and a serving definition of the meaning of *anti-aging* suggested. This builds on previous work that attempts to define anti-aging interventions.^{2–10} We will then present an attempt at a broad and general description of the biological basis of aging, to offer the beginnings of an etiological basis for the understanding of senescence as a disease syndrome. Then, in the main part of this chapter, we examine how the aging *vs.* disease question is presented in general medical textbooks.

2.1.1 What Does “Aging” Mean?

The word *aging* acts as a stumbling block in discussion because it has multiple meanings that are sometimes conflated. The main, distinct meanings are:

- The passage of time (*calendar aging*).
- Time-dependent alterations, usually in adult living organisms, but also inert objects (*age changes*).
- Cumulative deteriorative changes in adult organisms leading to pathology and death (*senescence*).^{11–13} Senescence is one type of age change.

An unfortunate additional source of confusion is that the word senescence also has a second meaning, as introduced by Leonard Hayflick, that of *cellular senescence*. This refers to a specific type of cellular change where the proliferative capacity of cells is lost and a pathogenic hypertrophic phenotype appears. Confusion between these two meanings can, in some contexts, be avoided by use of the term *organismal senescence* to contrast with cellular senescence. However, it seems likely that the two meanings of senescence will continue to generate confusion. Replacement of *cellular senescence* with another term would solve this problem.

Thus, the English language is a hindrance in that the multiple meanings of aging impede understanding. Not all languages have this problem; for example the Russian *starenije* (старение) means, essentially, senescence. For people, age changes include maturational changes, such as the attainment of wisdom, and character development. In this sense, an anti-aging drug would be highly undesirable; clearly, the interest is in anti-senescence (or geroprotectant) drugs, where senescence is meant in its original sense, not the sense of cellular senescence.

2.1.2 Is Aging a Disease?

Human senescence manifests as a wide range of deteriorative changes, including some that are debilitating and sometimes fatal (*e.g.* cardiovascular disease, cancer and dementia) and some that are not (*e.g.* greying of hair

and wrinkling of skin). In medicine, a conceptual division is made between the former, as diseases for which aging is a risk factor, and the latter, which are not pathological but rather manifestations of *normal* aging.¹⁴⁻¹⁶ Here, aging itself is viewed as a natural and non-pathological process. However, this division and the notion of normal aging is problematic in a number of respects. For example, the designation of particular senescent changes as normal or pathological has been controversial, as illustrated by the transfer of late-onset Alzheimer's disease and osteoporosis from the former to the latter category.⁵ Moreover, from a biological perspective, senescence, a biological process whose defining characteristic is deterioration, is a fundamentally pathological process, identifiable as damage accumulation, degeneration, loss of function, and emergence of numerous disease states that can cause suffering and death. At present there exists some division between perspectives on aging in the medical and scientific domain. In the former the concept of normal aging is more prevalent, whereas in the latter there are more doubts about the existence (or meaning) of "non-pathological senescence".

As a contribution to this debate, we present here an attempt at a disease definition of aging. Ideally, a disease definition will include a full description of the disease etiology. In the case of aging this is not possible since the biological mechanisms that cause senescence are only partly understood. This definition does not pretend to encompass the views of all biogerontologists, and it surely will not do so. We hope that its faults will incite others to develop better definitions.

2.1.2.1 *An Attempt at a Broad Account of the Etiology of Senescence*

Organismal senescence manifests as diverse pathologies, including neurodegenerative diseases, cardiovascular disease and cancer, as well as minor pathologies such as skin wrinkling, and encompasses the etiologies of these conditions. There is no single etiology of organismal senescence, but rather multiple causes that generate a number of syndromes and unitary diseases. Thus, aging is a disease super-syndrome. These etiologies are predominantly the result of inherited predisposition, but environmental factors that promote damage and injury also play an important role, often through effects on the expression of predispositions (*e.g.* mechanical injury to joints can contribute to osteoarthritis).

Insofar as it is genetically determined, organismal senescence is a form of genetic disease, but of a special kind, as follows. According to contemporary medical understanding, a genetic disease is the result of a mutation in a gene that disrupts its evolved function, changing the gene from wild type to mutant, thereby disrupting biological function and causing pathology. By contrast, the inherited predisposition to organismal senescence is largely specified by wild-type genes. This seemingly paradoxical claim makes sense in the light of the evolution of aging.

Until the middle of the last century, aging was viewed as an adaptation that benefited the species by removing worn out, old individuals. This view is still